Durham-based Serenex is launching a second clinical study of a small-molecule compound that may fight cancerous tumor growth.
The compound, SNX-5422, affects the behavior of proteins important to cell growth and survival, a process often out of control in cancerous tumors. Serenex researchers have demonstrated that this compound can slow or stop that rapid growth.
The Phase I clinical trial of about 50 patients will take place in Tennessee and Pennsylvania and will examine cancers in the blood. The other Phase I study, begun in May, is observing the same compound's effect on solid tumors.
Read the full news release.